-
Pioglitazone and heart disease; ARBs manufacturers spend millions to show the non-inferiority of their products compared to less expensive, generic ACE inhibitors; some athletes turn to growth hormone because it is difficult to detect; FDA Actions
-
FDA drug approval to change? Urinary incontinence in women; how metabolism of certain drugs can be predicted by genetic analysis; bowel preps may compromise renal function especially in the elderly according to a new study; FDA Actions.
-
Setoguchi and colleagues assessed the degree of utilization of guideline (Class I) protective drugs in elderly patients who survived an acute MI (AMI) and at least 30 days thereafter.
-
One-time screening for abdominal aortic Aneurysms (AAA) is recommended in older men, but there is little long-term data on the value of such screening, especially in women.
-
The home automatic external defibrillator trial (HAT) tested the hypothesis that placement of an automatic external defibrillator (AED) in the homes of patients with previous myocardial infarctions, who were thought to be at moderate risk for sudden death, would reduce overall mortality compared to standard measures to train family members in manual cardiopulmonary resuscitation (CPR).
-
Intravascular volume expansion has long been advised as an effective temporizing technique for patients with cardiac tamponade prior to drainage of the fluid, but there is little data supporting this practice.
-
Vernakalant is a new investigational anti- arrhythmic drug. The compound is relatively selective, blocking the early-activating potassium channel and the frequency-dependent sodium channel.
-
-
Dowson and colleagues performed a randomized, controlled trial to assess the efficacy of PFO closure in reducing the incidence of migraine with aura.
-
In this paper, corrado and colleagues describe the results of endocardial voltage mapping (EVM) and endomyocardial biopsy (EMB) in 27 patients with ventricular arrhythmias who were suspected to have a subtle manifestation of arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D).